A Patient-Reported Outcomes Study in Patients with Primary Immunodeficiency in Japan: A Non-interventional Prospective Observational Study - PID PRO study in Japan

Takeda Pharmaceutical Company Limited.0 sites127 target enrollmentOctober 29, 2021

Overview

No summary available.

Registry

who.int

Start Date

October 29, 2021

End Date

May 19, 2023

Last Updated

last year

Study Type

Observational

Sex

All

Sponsor

•1\)Criteria common to patients with PID and healthy volunteers: (1\)Works in the pharmaceutical, medical, or research industry (or has a cohabiting family member who does) (2\)Is expected to be unable to answer questions about the specified study variables 2\)Criteria specific to patients with PID: (1\)Patients who have been diagnosed with an inherited autoinflammatory disease, such as familial Mediterranean fever 3\)Criteria specific to healthy volunteers: (1\)Has type 2 diabetes, hypertension, dyslipidemia, liver disease (hepatitis), renal disease, cardiac disease, thyroid disease, adrenal disease, any other metabolic disorder, or any mental disease such as depression at the time of giving informed consent (and assent, if applicable) (2\)Has any physical symptom that will interfere with his/her daily life at the time of giving informed consent (and assent, if applicable) (3\)Is regularly taking medicine or attending a clinic for any disease (seasonal allergic diseases such as pollinosis and any medication/clinic visits to treat the disease are excluded) at the time of giving informed consent (and assent, if applicable) (4\)Has a history of any severe medical condition (5\)Has a drug or food allergy (6\)Has a family history of PID